Effect of intraoperative methylene blue on postoperative delirium in elderly patients undergoing joint replacement: a randomized controlled trial (2025)

Peer-Reviewed Study · Zhang W; Ling F; Qi J; Wang L; Qiao Y; Zhang Q; Qiu X; Li C; Zhang Y · July 23, 2025

Zhang W et al., 2025-07-23: Randomized controlled trial in 217 elderly patients undergoing joint replacement; 2 mg/kg methylene blue in 50 mL infused intravenously over 60 minutes at induction versus 5% glucose. Postoperative delirium fell from 20.4% to 8.3%, with more postoperative fever in the methylene blue group (16.5% vs 7.4%).

The incidence of POD in the MB group was significantly lower than that in the control group (8.3% vs. 20.4%, hazard ratio = 0.39; 95% confidence interval: 0.173-0.858; P = 0.024).

Zhang W et al., 2025-07-23: Randomized controlled trial in 217 elderly patients undergoing joint replacement; 2 mg/kg methylene blue in 50 mL infused intravenously over 60 minutes at induction versus 5% glucose. Postoperative delirium fell from 20.4% to 8.3%, with more postoperative fever in the methylene blue group (16.5% vs 7.4%). Study type: randomized controlled trial with blinded outcome assessment. N=217 (109 MB / 108 control). Dose 2 mg/kg IV over 60 min, single intraoperative infusion. Country: China (Xuzhou Medical University). Funder not recorded in the abstract. Declared conflicts: 'The authors declare that they have no conflicts of interest.' Again a perioperative prevention endpoint in elderly surgical patients, not cognitive enhancement in healthy users. Also filed as MTK-41 (claims C3, C8). Study type: randomized trial.